Analytica : Notice of Option Expiry

P E RI CO A CH

ANALYTICA LTD - ABN 12 006 464 866

21 December 2017

Dear Option Holder

Unlisted Options expiring 5pm 31 January 2018 with an exercise price of $0.005 cents per options

Notice is hereby given that Analytica Limited (Company) (ASX:ALT) unlisted options (ALT Options) that you hold will expire at 5:00pm (AEST) on Wednesday 31st January 2018 (Expiry Date). Should you wish to exercise your ALT Options, you must do so in accordance with the instructions set out in the enclosed personalised Notice of Exercise of Option Form on or before the Expiry Date. In accordance with ASX Listing Rule 6.24 and Appendix 6A of the ASX Listing Rules, the Company advises the following:

• 1. The number of ALT Options that you hold is set out in the enclosed personalised Notice of Exercise of Option Form. Each ALT Option is exercisable into one (1) fully paid ordinary share in ALT (Share) in accordance with the terms of the ALT Options.

• 2. The exercise price for each ALT Option is $0.005 (0.5 cents) (Exercise Price) pursuant to ASX Listing Rules following the Company's recent rights issue.

• 3. ALT Options must be exercised in multiples of 250,000, unless you are exercising your entire holding.

• 4. The due date for payment of the Exercise Price for each ALT Option that you elect to exercise is before 5:00pm (AEST) on Wednesday 31 January 2018 (Due Date).

• 5. If you do not elect to exercise your ALT Options on or before the Due Date and/or do not pay the Exercise Price for your ALT Options by the Due Date, your ALT Options will lapse and expire. Once expired, you will have no further right or entitlement to those ALT Options.

• 6. The latest available closing price of ALT Shares prior to the date of this notice was $0.005 (21 December 2017).

• 7. The highest and lowest sale price of the Company's Shares during the three (3) months immediately before the date of this notice was:

Highest:

$0.007 (14 December 2017)

Lowest:

$0.003 (19th and 23rd October and 23rd November 2017)In order to exercise your options, please follow the steps set out in the Notice of Exercise of Options Form enclosed by either:

• 1. Making a payment by BPAY using the Biller Code and Customer Reference Number set out on the Notice of Exercise of Options Form; or

• 2. Completing and returning the payment slip attached to your Notice of Exercise of Options Form along with a cheque, bank draft or money order.

All Shares issued upon exercise of the ALT Options will rank pari passu in all respects with the Company's existing Shares. The Company will apply for official quotation by the ASX of all Shares issued upon exercise of the ALT Options. If, for any reason, you are unlikely to take up your ALT Options, please let us know. For further information, you can contact the Company Secretary on (0433217876 between 9:00am and 5:00pm (AEST) Monday to Friday. If you are unsure whether you should take up your ALT Options, you should contact your stockbroker, solicitor, accountant or other professional advisor.

Bryan Dulhunty

Company Secretary

For more information, please contact:[e-mail]

For more information about the PeriCoach System, visit:www.PeriCoach.com

For more information about Analytica, visitwww.AnalyticaMedical.com

Follow us on:

About Analytica Limited

Analytica's lead product is the PeriCoach® System - an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA.